Health Canada’s 2025 modernization of clinical trial regulations marks a turning point for early-stage medical innovators. The shift to a risk-based oversight model for drugs and devices aims to balance flexibility with public safety, improving how evidence is generated and assessed. For startups and research teams entering clinical environments, that means meeting higher expectations for study design, data integrity and post-market monitoring—well before a product reaches pa
